BPC-157: the complete guide
BPC-157 is a synthetic pentadecapeptide fragment of body protection compound found naturally in gastric juice. It is studied for its effects on tendon, ligament, muscle, and gastrointestinal tissue repair.
How BPC-157 works
BPC-157 appears to modulate nitric oxide (NO) signaling, upregulate growth factors (VEGF, FGF), and accelerate angiogenesis at injury sites. Most evidence is from animal studies; human trials are limited.
Typical BPC-157 dosage
Commonly reported research ranges: 200–500 mcg per injection, 1–2x daily.
Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.
How to reconstitute BPC-157
A widely used reconstitution for a 5 mg vial is 2 ml of bacteriostatic water. With a typical 250 mcg dose this works out to the unit count shown in the calculator below.
Half-life and administration frequency
Oral form ~4 hours; subcutaneous estimated 4–6 hours.
This half-life informs how often BPC-157 is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.
Reported side effects
- Mild injection-site irritation
- Dizziness (infrequent, dose-dependent)
- No serious adverse events reported in published animal data
This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.
Common BPC-157 stacks
- TB-500 (for synergistic soft-tissue healing)
- GHK-Cu (for connective tissue)
Full editorial stack guides featuring BPC-157:
BPC-157 + TB-500
Tendon strains, post-surgical recovery, joint pain, slow-to-heal soft-tissue injuries.
BPC-157 + GHK-Cu
Post-surgical scars, skin quality, hair density, low-grade chronic inflammation.
Tirzepatide + BPC-157
GLP-1 users struggling with nausea or GI side effects, protecting gut lining during aggressive titration, anyone combining fat loss with soft-tissue recovery work.
BPC-157 + Thymosin Alpha-1
Post-viral recovery, chronic GI inflammation with immune dysregulation, users with concurrent gut and immune complaints.
Storage and handling
Lyophilized: room temp (stable, short term) or refrigerated. Reconstituted: refrigerated 2–8 °C, use within 28 days.
FDA and regulatory status
Not FDA approved. Research use only in the US. Removed from FDA 503A bulks list in 2023.
BPC-157 clinical trials and evidence
For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.
Track your BPC-157 protocol on iPhone
Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.
See the app →Frequently asked questions
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide fragment of body protection compound found naturally in gastric juice. It is studied for its effects on tendon, ligament, muscle, and gastrointestinal tissue repair.
How does BPC-157 work?
BPC-157 appears to modulate nitric oxide (NO) signaling, upregulate growth factors (VEGF, FGF), and accelerate angiogenesis at injury sites. Most evidence is from animal studies; human trials are limited.
What is a typical BPC-157 dose?
Commonly reported ranges are 200–500 mcg per injection, 1–2x daily. This is research information, not a recommendation — dosing should be individualized under clinical guidance.
What is the half-life of BPC-157?
Oral form ~4 hours; subcutaneous estimated 4–6 hours. This influences how often it is administered.
How do you reconstitute BPC-157?
A common approach is to add 2 ml of bacteriostatic water to a 5 mg vial. Use the reconstitution calculator for exact unit counts.
What are the side effects of BPC-157?
Mild injection-site irritation; Dizziness (infrequent, dose-dependent); No serious adverse events reported in published animal data.
Is BPC-157 FDA approved?
Not FDA approved. Research use only in the US. Removed from FDA 503A bulks list in 2023.
Are there clinical trials for BPC-157?
Registered or published clinical-trial sources for BPC-157 are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.
References
- BPC-157 pharmacology and tissue-repair literature (PubMed) — National Library of Medicine. Primary literature index — animal and limited human studies on BPC-157 healing mechanisms
- Sikiric et al. — Stable Gastric Pentadecapeptide BPC 157 in Clinical Trials — PubMed. Body of work from the research group that characterized BPC-157's healing profile
- FDA removes certain bulk drug substances from 503A list — U.S. Food and Drug Administration. Regulatory source for BPC-157's current 503A status
Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.